LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova PLC executive Stephanie Bolton reported equity compensation activity involving restricted stock units (RSUs), performance stock units (PSUs), and ordinary shares. On March 30, 2026, she exercised vested RSUs and PSUs into ordinary shares of LivaNova PLC, consistent with the company’s incentive award plans.
These exercises delivered 17,815 ordinary shares, while 8,377 ordinary shares were withheld at $61.27 per share to satisfy tax obligations, leaving her with 22,189 ordinary shares held directly after the transactions. There were no open-market purchases or sales; the only disposition was tax withholding.
Bolton also received new equity awards on the same date, including 8,976 RSUs and several PSU grants that will vest based on future revenue growth, relative total shareholder return, and adjusted earnings per share performance through 2028–2029, subject to continued service and plan terms.
LivaNova PLC Chief Human Resources Officer Natalia Kozmina reported multiple equity compensation transactions. Vested restricted stock units were settled into 6,389 ordinary shares, with 1,374 shares withheld at $61.27 per share to cover tax liabilities.
She received new grants of 9,792 restricted stock units and three separate awards of 3,264 performance stock units each, tied to revenue growth, relative total shareholder return, and adjusted EPS performance for 2026–2028. Following these transactions, she directly holds 5,015 ordinary shares.
LivaNova PLC executive Franco Poletti, President of Cardiopulmonary, exercised 2,140 Stock Appreciation Rights that converted into the same number of ordinary shares at $57.60 per share. To cover the SAR base price and tax liabilities, 2,049 shares were withheld at $62.26 per share, leaving a net increase of 91 shares. Following these routine compensation-related transactions, Poletti holds 8,941 ordinary shares directly and 219 shares indirectly through his spouse. The F-code dispositions reflect share withholding for settlement and taxes, not open-market sales.
LivaNova PLC submitted a notice under Section 219 of the Iran Threat Reduction and Syria Human Rights Act and Section 13(r) that it made the required disclosure in its Annual Report on Form 10-K for the period ended December 31, 2025. The company states the disclosure appears in Part I, Item 1. Business of the Form 10-K.
The notice, dated February 25, 2026, is a formal attestation that the specified Iran/Syria-related disclosure was included in the filed annual report.
LivaNova PLC is a London‑based global medical technology company focused on two segments: Cardiopulmonary and Neuromodulation. It sells heart‑lung machines, oxygenators, perfusion systems, cannulae, and neuromodulation devices such as its VNS Therapy System, serving patients with drug‑resistant epilepsy, difficult‑to‑treat depression, and obstructive sleep apnea.
The company invests in R&D, including AI and software, and runs major clinical programs like the RECOVER depression study and the OSPREY trial for its aura6000 sleep apnea system. For 2025, 53% of net revenue came from the U.S., 19% from Europe, and 28% from the rest of the world. It reports extensive global regulatory, cybersecurity, trade, environmental, and compliance risks and highlights exposure to sanctions regimes through limited sales into Iran and other sanctioned markets.
As of December 31, 2025, LivaNova employed about 3,300 people in 34 countries and emphasizes culture, leadership development, and diversity initiatives as part of its human capital strategy.
LivaNova PLC reported strong fourth-quarter and full-year 2025 results while absorbing a large environmental charge and issuing 2026 guidance. Q4 revenue was $360.9 million, up 12.1% on a reported basis and 9.5% in constant currency, with double‑digit growth in both Cardiopulmonary and Neuromodulation.
For 2025, revenue reached $1.39 billion, rising 10.7% reported and 10.7% organically. GAAP diluted loss per share was $4.45 due largely to a $365.6 million SNIA environmental liability, while adjusted diluted earnings per share increased to $3.90 from $3.38.
The company guided 2026 constant-currency revenue growth between 6.0% and 7.0%, adjusted diluted earnings per share of $4.15 to $4.25, and adjusted free cash flow of $160 million to $180 million. LivaNova also gained significantly higher Medicare reimbursement for VNS Therapy DRE procedures and received U.S. FDA approval for its cloud-based digital health platform, supporting future Neuromodulation growth.
LivaNova PLC institutional holder PRIMECAP Management Co filed Amendment No. 8 to a Schedule 13G reporting its ownership stake. PRIMECAP reports beneficial ownership of 4,224,852 LivaNova shares, representing 7.74% of the class as of 12/31/2025.
The firm has sole voting power over 4,203,362 shares and sole dispositive power over 4,224,852 shares, with no shared voting or dispositive power. PRIMECAP certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of LivaNova.
LivaNova PLC’s ownership report shows several Millennium-affiliated entities holding more than five percent of its ordinary shares as of December 31, 2025. Integrated Core Strategies (US) LLC reports beneficial ownership of 3,065,717 shares, representing 5.6% of the class.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 3,484,082 shares, or 6.4% of the outstanding ordinary shares, through entities over which they have voting control and investment discretion. They certify the holdings are not for the purpose of changing or influencing control of LivaNova.
LivaNova PLC reported a leadership change in its legal function. On January 12, 2026, Senior Vice President, Chief Legal Officer, and Company Secretary Michael Hutchinson notified the company that he is resigning to pursue another opportunity. His last day with LivaNova will be January 26, 2026, creating a near-term transition period for the company’s legal and governance roles.
The company plans to retain an external search firm to begin the process of finding a new Chief Legal Officer, indicating that the board and management aim to bring in a successor through a structured, formal search.
LivaNova PLC officer reports RSU vesting and share withholding for taxes. The President, Cardiopulmonary of LivaNova PLC reported the vesting and settlement of 967 restricted stock units into ordinary shares on 12/15/2025 at an exercise price of $0. On the same date, 416 ordinary shares were disposed of through share withholding at a price of $63.06 to satisfy tax liabilities related to the vesting.
After these transactions, the officer beneficially owns 8,850 ordinary shares directly and 219 ordinary shares indirectly through a spouse. The RSUs were originally granted on December 15, 2023 under the Amended and Restated LivaNova PLC 2022 Incentive Award Plan and vested over a two-year schedule ending December 15, 2025.